Semaglutide 1.7 mg FlexTouch Pen

Product Overview

Semaglutide 1.7 mg FlexTouch Pen represents a modern, once‑weekly injectable therapy designed specifically for the management of overweight and obesity in adults. Manufactured by Novo Nordisk India, the pen delivers a precise 1.7 mg dose of semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist, using the user‑friendly FlexTouch delivery system. Each pack contains one pre‑filled pen and four disposable needles, providing a convenient and discreet method for long‑term weight‑management treatment. The product meets the rigorous quality standards required for pharmaceutical distribution and is classified under the Diabetes Care category, reflecting its origin as a glucose‑lowering agent that also offers significant metabolic benefits for weight reduction.

What is Semaglutide 1.7 mg FlexTouch Pen

Semaglutide is a synthetic analogue of the naturally occurring hormone GLP‑1, which plays a central role in appetite regulation and glucose homeostasis. The 1.7 mg strength is the approved dose for chronic weight management in individuals with a body‑mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater when accompanied by at least one weight‑related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes. The FlexTouch pen is pre‑filled, needle‑free in terms of patient handling, and features a simple push‑button mechanism that minimizes injection‑site pain. Its once‑weekly dosing schedule enhances adherence compared with daily oral medications, and the compact design allows for administration at home, work, or while traveling.

Uses and Benefits

The primary therapeutic use of Semaglutide 1.7 mg FlexTouch Pen is to facilitate weight loss and help maintain the achieved weight loss over the long term. Clinical trials have demonstrated that, when combined with a reduced‑calorie diet and increased physical activity, patients can achieve an average reduction of approximately 15 % of baseline body weight after 68 weeks of treatment. In addition to weight reduction, semaglutide therapy has been shown to improve cardiovascular risk markers, including blood pressure, lipid profile, and insulin sensitivity, thereby lowering the overall risk of heart disease and type 2 diabetes. The convenience of a once‑weekly injection, coupled with the discreet pen format, supports sustained lifestyle changes and improves patient adherence to weight‑management programs.

How It Works

Semaglutide exerts its effects by mimicking the incretin hormone GLP‑1, which is released by intestinal L‑cells after meals. Binding to GLP‑1 receptors in the brain slows gastric emptying, increases satiety, and reduces appetite, leading to a lower caloric intake. At the same time, the drug enhances glucose‑dependent insulin secretion from pancreatic beta cells, improving glycemic control and reducing the risk of hyperglycemia. The combined appetite‑suppressing and metabolic actions create a synergistic effect that promotes sustainable weight loss when used alongside dietary modification and regular physical activity.

Dosage Guidelines

Treatment should be initiated with a dose of 0.25 mg administered subcutaneously once weekly for the first four weeks. The dose is then titrated to 0.5 mg weekly for an additional four weeks before reaching the approved maintenance dose of 1.7 mg once weekly. Injections may be given in the abdomen, thigh, or upper arm, with site rotation recommended to minimize irritation. The pen should be inspected for visible particles before each use, and the needle must be discarded after a single injection. Dose adjustments are not required for mild to moderate hepatic impairment, but caution is advised in patients with severe renal dysfunction, and the medication should be used with caution in those with a history of pancreatitis or gallbladder disease.

Side Effects

Adverse events associated with semaglutide are generally mild to moderate and tend to diminish over the first few weeks of therapy. The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These gastrointestinal symptoms typically lessen as the body adapts to the medication. Less frequent but clinically important side effects may involve pancreatitis, gallbladder disease, and injection‑site reactions such as erythema or pruritus. Rarely, severe hypoglycemia can occur when semaglutide is used in combination with insulin or sulfonylureas. Patients should be advised to monitor for signs of hypersensitivity, including rash, swelling, or difficulty breathing, and to seek medical attention if symptoms persist or worsen.

Warnings and Precautions

Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). The drug should not be used during pregnancy or breastfeeding unless the potential benefit outweighs the risk, and healthcare providers should discuss this with patients of child‑bearing potential. Caution is recommended for patients with a history of pancreatitis, severe gastrointestinal disease, or suicidal ideation, as well as those with significant renal impairment. The medication carries a boxed warning for the potential risk of thyroid C‑cell tumors observed in rodent studies, although a causal relationship in humans has not been established. Patients should be monitored regularly for changes in thyroid function and for any signs of thyroid enlargement.

FAQs

Q1: Who is eligible to use Semaglutide 1.7 mg FlexTouch Pen?
A: It is indicated for adults with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight‑related comorbidity, who are also committed to dietary modification and increased physical activity.

Q2: How should the pen be stored before and after first use?
A: The pen must be stored refrigerated at 2 °C to 8 °C until the first injection. After the first use, it may be kept at room temperature (up to 30 °C) for a maximum of 4 weeks, protected from direct heat and light.

Q3: Can semaglutide be used together with other weight‑loss medications?
A: Combining semaglutide with other GLP‑1 receptor agonists or prescription appetite suppressants is not recommended due to limited safety data. If combination therapy is considered, it should only be done under close medical supervision.

Q4: What should I do if I miss a scheduled dose?
A: If more than three days have passed since the planned injection, the missed dose may be administered, and subsequent doses should be spaced at least seven days apart. If fewer than three days remain, the missed dose should be skipped, and the regular dosing schedule resumed.

Q5: Where can I find detailed prescribing information?
A: Comprehensive prescribing details are available on the U.S. Food and Drug Administration label page, the National Institutes of Health (NIH) Office of Dietary Supplements, and the Drugs.com medication guide. For the most up‑to‑date safety information, consult U.S. Food and Drug Administration, PubMed, or MedlinePlus. Additional authoritative resources include the National Institutes of Health and the Drugs.com database.

Related Products

• Novofine 31G Needle (Device)
• Rybelsus 14 mg (Semaglutide)
• Rybelsus 7 mg (Semaglutide)
• Rybelsus (Semaglutide)
• Semaglutide 0.25 mg FlexTouch Pen
• Wegovy 0.25 mg FlexTouch Pen (Semaglutide)
• Ozempic Pen (Semaglutide)
• Ozempic 1 mg (Semaglutide)
• Rybelsus 3 mg (Semaglutide)
• Wegovy 0.5 mg FlexTouch Pen (Semaglutide)
• Semaglutide 3 mg (Generic)
• Glucagen Injection (Glucagon)